BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

Bibliographic Details
Title: BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study
Authors: Louw, Amber, Panou, Vasiliki, Szejniuk, Weronika Maria, Meristoudis, Christos, Chai, Siaw Ming, van Vliet, Chris, Lee, Y. C. Gary, Dick, Ian M., Firth, Tina, Lynggaard, Louise Andersen, Asghari, Azadeh Birbaneh, Vyberg, Mogens, Hansen, Johnni, Creaney, Jenette, Røe, Oluf Dimitri
Source: In Journal of Thoracic Oncology July 2022 17(7):921-930
Database: ScienceDirect
More Details
ISSN:15560864
DOI:10.1016/j.jtho.2022.04.008
Published in:Journal of Thoracic Oncology
Language:English